Daniel J. Wallace - Concepedia

Author

Daniel J. Wallace

Also Known As

Buyon, Jill P, D J Wallace, D WALLACE, D Wallace, D. J. Wallace, D. WALLACE, D. Wallace, D.J. Wallace, DANIEL J. WALLACE, DANIEL WALLACE

788

Publications

41K

Citations

H-Index

194

Concepts

All Affiliations

Cedars-Sinai Medical Center University of California, Los Angeles Johns Hopkins University Oklahoma Medical Research Foundation University of Toronto

About

Daniel J. Wallace is an author at Cedars-Sinai Medical Center specializing in medicine, lupus, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	56	6.9K
2	Engineering	7	7	217
3	Health Sciences	7	7	285
4	Public Health	5	5	460
5	Natural Sciences	1	1	25

Daniel J. Wallace

252

Publications

36.7K

Citations

H-Index

Page 1

	Year	Citations
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus Michelle Petri, Ana‐Maria Orbai, Graciela S. Alarcón, Arthritis & Rheumatism	2012	5.1K
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus Martin Aringer, Karen H. Costenbader, David Daikh, Arthritis & Rheumatology	2019	2.3K
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus Richard Furie, Michelle Petri, Omid Zamani, Arthritis & Rheumatism	2011	1.6K
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis Bevra H. Hahn, Maureen McMahon, Alan Wilkinson, Arthritis Care & Research Glomerular DiseaseRheumatology GuidelinesRenal PathologyPulse GlucocorticoidsUnited States	2012	1.5K
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial Joan T. Merrill, C. Michael Neuwelt, Daniel J. Wallace, Arthritis & Rheumatism	2009	1.3K
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis Ellen M. Ginzler, Mary Anne Dooley, Cynthia Aranow, New England Journal of Medicine	2005	1.1K
Dubois' Lupus Erythematosus Daniel J. Wallace Annals of Internal Medicine RheumatologyClinical FindingAutoimmune DiseaseSystemic Lupus ErythematosusVasculitis	1988	663
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) Christian Antoni, Arthur Kavanaugh, Bruce Kirkham, Arthritis & Rheumatism	2005	636
A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis Dimitrios T. Boumpas, Richard Furie, Susan Manzi, Arthritis & Rheumatism	2003	609
The frequency and outcome of lupus nephritis: results from an international inception cohort study John G. Hanly, Aidan G. O’Keeffe, Li Su, Lara D. Veeken	2015	605

Page 1